

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai - 400 063

Telephone: +91 22 6257 1000
Fax: +91 22 6257 1010

Limited review report

Board of Directors of Advanced Enzyme Technologies Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Advanced Enzyme Technologies Limited (“the Company”) for the quarter ended 30 June 2021 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended 31 March 2021 as reported in these financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants

Firm’s Registration No: 101248W/W-100022

SADASHIV
SHANKAR
SHETTY

Digitally signed by
SADASHIV SHANKAR
SHETTY
Date: 2021.08.07
11:26:15 +05'30'

Mumbai
7 August 2021

Sadashiv Shetty
Partner

Membership No: 048648
ICAI UDIN: 21048648AAAABY6691

Registered Office:

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No:91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Statement of unaudited standalone financial results for the quarter ended 30 June 2021

(₹ in Million except per share data)

Particulars	Quarter ended			Year ended
	30-Jun-21 Unaudited	31-Mar-21 Audited (Refer note v)	30-Jun-20 Unaudited	31-Mar-21 Audited
1 Revenue from operations	727.52	706.08	614.05	2,834.73
2 Other Income	9.43	25.84	7.29	68.23
3 Total Income (1+2)	736.95	731.92	621.34	2,902.96
4 Expenses				
(a) Cost of materials consumed	256.10	249.12	187.15	950.34
(b) Purchases of stock-in-trade	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(28.34)	3.64	7.67	12.74
(d) Employee benefits expense	111.74	84.16	83.15	342.34
(e) Finance costs (including exchange difference)	0.08	0.09	0.43	0.84
(f) Depreciation and amortisation expense	22.68	24.35	21.18	89.32
(g) Other expenses	123.83	149.88	104.42	523.10
Total expenses	486.09	511.24	404.00	1,918.68
5 Profit before exceptional item and tax (3-4)	250.86	220.68	217.34	984.28
6 Exceptional item	-	-	-	-
7 Profit before tax (5-6)	250.86	220.68	217.34	984.28
8 Tax expense				
Current tax	65.14	54.82	61.09	248.44
Deferred tax charge/(credit)	0.24	13.46	3.04	25.72
Total tax expense	65.38	68.28	64.13	274.16
9 Net profit for the period (7-8)	185.48	152.40	153.21	710.12
10 Other comprehensive income				
A (i) Items that will not be reclassified to Profit or Loss				
Remeasurements of defined benefit liability/(asset)	(5.33)	2.90	(0.90)	(0.39)
(ii) Income tax related to items that will not be reclassified to Profit or Loss	1.34	(0.86)	0.26	0.10
B (i) Items that will be reclassified to Profit or Loss	-	-	-	-
(ii) Income tax related to items that will be reclassified to Profit or Loss	-	-	-	-
Total Other comprehensive income	(3.99)	2.04	(0.64)	(0.29)
11 Total comprehensive income (9+10)	181.49	154.44	152.57	709.83
12 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.56	223.46	223.36	223.46
13 Other equity				4,131.00
14 Earnings Per Share of ₹ 2 each (not annualized)				
(a) ₹ (Basic)	1.66	1.37	1.37	6.36
(b) ₹ (Diluted)	1.66	1.36	1.37	6.35

